Orthobiologics

Orthobiologics

Global Orthobiologics Market to Reach US$9.0 Billion by 2030

The global market for Orthobiologics estimated at US$6.8 Billion in the year 2023, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Viscosupplementation, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Synthetic Orthobiologics segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 3.7% CAGR

The Orthobiologics market in the U.S. is estimated at US$1.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 3.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Orthobiologics Market – Key Trends & Drivers Summarized

What Are Orthobiologics, and Why Are They Critical in Orthopedic Medicine?

Orthobiologics are biologically derived substances used to enhance the healing of bones, muscles, tendons, and ligaments in orthopedic procedures. These substances, which include platelet-rich plasma (PRP), bone grafts, stem cells, and hyaluronic acid, are designed to improve the body’s natural healing processes by reducing inflammation, promoting tissue regeneration, and accelerating recovery. Orthobiologics are widely used in treatments for sports injuries, degenerative joint diseases, and spinal conditions, offering patients a minimally invasive option to surgery or, in some cases, improving surgical outcomes when used as an adjunct therapy. By leveraging the body’s natural regenerative capacity, orthobiologics represent a promising advancement in musculoskeletal care, providing faster healing and reducing complications associated with traditional treatments. Their growing adoption is being driven by increased patient demand for non-surgical treatment options and the rise of biologics in orthopedic surgery.

How Are Technological Advancements Shaping the Orthobiologics Industry?

Technological innovations are propelling the orthobiologics market forward, particularly in the areas of regenerative medicine and tissue engineering. Advances in stem cell research have expanded the possibilities for regenerative treatments, with stem cell-based therapies showing promise in repairing cartilage, bone, and soft tissues in orthopedic patients. The refinement of platelet-rich plasma (PRP) therapies, where concentrated platelets are injected into damaged tissue to promote healing, has also increased the effectiveness of non-surgical treatments for a variety of musculoskeletal injuries. Furthermore, developments in synthetic bone graft substitutes, which mimic the properties of natural bone, are offering orthopedic surgeons more options for bone regeneration in spinal fusion and trauma cases. Additionally, innovations in the delivery systems for orthobiologics, such as the use of scaffolds or hydrogels, are improving the precision and efficacy of these therapies. These technological advancements are enhancing the scope of orthobiologics, making them more versatile and applicable to a wider range of conditions, from joint repair to spinal deformities.

Where Are Orthobiologics Being Used Most Extensively?

Orthobiologics are primarily used in orthopedic surgeries, sports medicine, and trauma care, with increasing applications in spinal fusion, joint repair, and soft tissue regeneration. In sports medicine, PRP and stem cell therapies are widely used to treat injuries such as tendonitis, ligament tears, and cartilage damage, helping athletes recover faster and avoid surgery. In orthopedic surgery, orthobiologics are frequently used in procedures like spinal fusion, where bone grafts or bone substitutes are needed to promote bone growth and stabilize the spine. Joint reconstruction, particularly in the knee and shoulder, is another area where orthobiologics are commonly employed to enhance tissue repair and reduce recovery times. Moreover, orthobiologics are gaining traction in treating degenerative joint diseases such as osteoarthritis, where they help alleviate pain and restore joint function. Their use in trauma care is also expanding, particularly for complex fractures that require enhanced bone healing.

What Is Driving the Growth of the Orthobiologics Market?

The growth in the orthobiologics market is driven by several factors, including the rising prevalence of musculoskeletal disorders, an increasing demand for minimally invasive procedures, and advancements in regenerative medicine. One of the primary drivers is the aging global population, which is leading to a higher incidence of orthopedic conditions such as osteoarthritis and osteoporosis, both of which benefit from orthobiologic treatments. The growing demand for minimally invasive and non-surgical treatment options is another significant driver, as patients increasingly seek alternatives to traditional surgery for faster recovery and fewer complications. Technological advancements in stem cell therapies, platelet-rich plasma (PRP), and bone graft substitutes are further expanding the range of conditions that can be treated with orthobiologics, making them more effective and accessible. Additionally, the increasing adoption of orthobiologics in sports medicine, driven by professional athletes and active individuals looking for cutting-edge treatments, is contributing to market growth. Lastly, the rising awareness of the benefits of biologics in orthopedic care, coupled with ongoing research and development in the field, is driving the broader use of these therapies in both clinical and surgical settings.

Select Competitors (Total 44 Featured) -

• Arthrex, Inc.
• Bioventus LLC
• DePuy Synthes
• Globus Medical, Inc.
• K2M Group Holdings, Inc.
• Kuros Biosciences AG
• Medtronic PLC
• NuVasive, Inc.
• Orthofix International NV
• RTI Surgical, Inc.
• SeaSpine Holdings Corporation
• Stryker Corporation
• XTANT Medical Holdings, Inc.
• Zimmer Biomet Holdings, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.